Oslo, Norway, December 4, 2024 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced new data from its
mRNA-based neoantigen vaccine platform for individualized cancer immunotherapy,
presented at the Personalized Cancer Vaccines Summit in Boston. The findings
highlight the platform's ability to elicit robust and durable immune responses.

Nykode has previously demonstrated that the neoantigen vaccine induces strong,
CD8-biased T cell responses, targeting the majority of the encoded neoantigens.
The novel pre-clinical data examines the kinetics of individual neoantigens,
showing distinct dose-response patterns. The findings underscore the importance
of an optimal vaccination schedule, highlighting differentiated responses to
early versus late boost vaccinations. 

The vaccine's ability to provide complete tumor protection with prophylactic
administration has been demonstrated. Now, new data reveal that this tumor
protection is durable: a single vaccination provided partial long-term
protection, while two vaccinations achieved complete and sustained protection at
day 90.

"These data reinforce the robust and durable immune responses our neoantigen
vaccine generates also in a mRNA format, further validating its potential as a
personalized cancer immunotherapy platform," said Agnete Fredriksen, Chief
Scientific Officer and Co-founder of Nykode Therapeutics.

Details for the Nykode Therapeutics' presentation are as follows:
Title: Nykode's Individualized Cancer Vaccine Approach Across DNA and mRNA
Time & Date: 1:30pm ET, December 4, 2024

The presentation is available on the Nykode website at
https://nykode.com/research-and-development/scientific-papers-and-presentations/
.


About VB10.NEO
VB10.NEO is a proprietary individualized neoantigen vaccine in development for
the treatment of locally advanced or metastatic solid tumors. The vaccine is
designed to be produced on-demand according to the neoantigen profile of an
individual patient. Neoantigens are proteins generated by tumor-specific
mutations not present in normal tissues and are thus an attractive target for
cancer immunotherapy as they may be recognized as foreign by the immune system.
VB10.NEO has been evaluated in multiple indications in two clinical trials. It
has been shown to be generally well tolerated and with an ability to generate
uniquely broad patient- and tumor-specific long-lasting immune responses.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to antigen presenting cells (APC), employed with
their cancer vaccines to induce a broad, strong and long-lasting antigen
specific immune response, which correlates with clinical responses in cancer
patients.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies, which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer.
VB10.NEO, an individualized cancer neoantigen vaccine, is being investigated in
a trial with more than 10 different indications.

The Company's partnerships include a multi-target collaboration with Regeneron
in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an inverse
vaccine platform for the potential use in autoimmune disorders, organ transplant
rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD).
Further information about Nykode Therapeutics can be found at
http://www.nykode.com.


Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by these forward-looking statements.


Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway